

# Facilitating the Translation of Academic Research into Clinical Practice How to Move Forward

*Carla Hollak, internist Amsterdam UMC*



## Disclosures

- Employed by Amsterdam UMC
- Involved in premarketing research with pharmaceutical companies
  - Sanofi, Protalix, Idorsia
- No personal fees from pharmaceutical companies
- Member of Insured Package Advisory Committee (paid)
- Chairman of SPHINX, non-profit association
- Initiator of platform “Medicine for Society”, part of Amsterdam UMC

[www.medicijnvoordemaatschappij.nl](http://www.medicijnvoordemaatschappij.nl)





EFFICIENCY GAINS THROUGH  
INNOVATION IN  
MEDICINES DEVELOPMENT:  
HOW CAN SCIENCE CONTRIBUTE?



ADVISORY REPORT

# NOW



Patient




Academia



Industry



Regulators




EFFICIENCY GAINS THROUGH  
INNOVATION IN  
MEDICINES DEVELOPMENT:  
HOW CAN SCIENCE CONTRIBUTE?



ADVISORY REPORT

# PREFERRED





# Medicijn voor de Maatschappij

[www.medicijnvoordemaatschappij.nl](http://www.medicijnvoordemaatschappij.nl)



[Medicijn voor de Maatschappij](https://www.linkedin.com/company/medicijnvoordevdemaatschappij)



[info@medicijnvoordemaatschappij.nl](mailto:info@medicijnvoordemaatschappij.nl)



[@MedicijnvdMaats](https://twitter.com/MedicijnvdMaats)

# Repurposing P-5-P: from case to system


To Amsterdam UMC



The medicinal product “Pyridoxal 5'-phosphate” is designated as an orphan medicinal product for the indication: Treatment of pyridoxamine 5'-phosphate oxidase deficiency. It shall be entered in the Community Register of Orphan Medicinal Products under number EU/3/22/2574.

## roadmap for academia

Rosenberg N, van der Wel, Stolwijk, van den Berg, Hollak with CBG in preparation




Bart Jacobs, Sibren van den Berg, Vincent van der Wel



Nina Stolwijk, Noa Rosenberg

# Repurposing mexiletine: from case to system



# Pro-active role of academia: what is needed?

## Incentivizing, funding, understanding

- Incentivizing:
  - Academic appraisal of development beyond discovery
  - Structure and funding
- Mutual understanding
  - For academics: understanding the regulatory framework
  - For regulators: understanding the developments in academia